{"classes":[{"categories":[{"measurements":[{"comment":"Lower and upper confidence bounds cannot be estimated because the analysis includes only one subject.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"10.65"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"American Indian or Alaska Native"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.60","upperLimit":"17.60","value":"12.30"},{"groupId":"OG001","lowerLimit":"11.31","upperLimit":"26.76","value":"18.23"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"title":"Asian"},{"categories":[{"measurements":[{"comment":"Lower and upper confidence bounds cannot be estimated because the analysis includes only one subject.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"2.10"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Native Hawaiian or Other Pacific Islander"},{"categories":[{"measurements":[{"comment":"Upper confidence bound could not be estimated because the upper confidence limit for survival did not cross 50%","groupId":"OG000","lowerLimit":"3.55","upperLimit":"NA","value":"7.35"},{"groupId":"OG001","lowerLimit":"10.94","upperLimit":"29.76","value":"20.35"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"title":"Black or African American"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.32","upperLimit":"14.70","value":"12.03"},{"groupId":"OG001","lowerLimit":"11.21","upperLimit":"20.28","value":"14.70"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"59"}],"units":"Participants"}],"title":"White"},{"categories":[{"measurements":[{"comment":"Upper confidence bound could not be estimated because the upper confidence limit for survival did not cross 50%","groupId":"OG000","lowerLimit":"13.08","upperLimit":"NA","value":"22.88"},{"groupId":"OG001","lowerLimit":"5.34","upperLimit":"39.22","value":"11.94"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"title":"Unknown or not reported"}],"denoms":[{"counts":[{"groupId":"OG000","value":"92"},{"groupId":"OG001","value":"85"}],"units":"Participants"}],"description":"NIH-required analysis. An event for overall survival (OS) is death due to any cause. Survival time is defined as time from randomization to the date of death or last known follow-up (censored). Rates are estimated by the Kaplan-Meier method. Analysis was to occur after 153 deaths were reported.","dispersionType":"90% Confidence Interval","groups":[{"description":"400 mg sorafenib by mouth twice a day for 28-day cycle. Continue up to 5 years in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Sorafenib Alone"},{"description":"27.5 Gy to 50 Gy stereotactic body radiation therapy (SBRT) in 5 fractions 24-72 hours apart over 5-15 days followed within 1-5 days by one cycle of 200 mg sorafenib by mouth twice a day. Starting with second cycle, if tolerable, increase to 400 mg sorafenib by mouth twice a day. Continue up to 5 years in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"SBRT Followed by Sorafenib"}],"paramType":"MEDIAN","populationDescription":"Eligible participants. Data were stratified by race.","reportingStatus":"POSTED","timeFrame":"From randomization to last follow-up: weekly during SBRT, post-SBRT/pre-sorafenib, monthly during sorafenib, and overall, from study entry: every 3 months for 2 years, then every 6 months. Maximum follow-up at time of analysis was 7.6 years.","title":"Overall Survival by Race","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"months"}